Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Sesen Bio, Inc. | ebio-123116x321.htm |
| EX-31.2 - EXHIBIT 31.2 - Sesen Bio, Inc. | ebio-123116x312.htm |
| EX-31.1 - EXHIBIT 31.1 - Sesen Bio, Inc. | ebio-123116x311.htm |
| EX-21.1 - EXHIBIT 21.1 - Sesen Bio, Inc. | ebio-123116x211.htm |
| 10-K - 10-K - Sesen Bio, Inc. | ebio-123116x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-202676) of Eleven Biotherapeutics, Inc., |
(2) | Registration Statement (Post-Effective Amendment No. 1 to Form S-1 on Form S-3 No. 333-201176) of Eleven Biotherapeutics, Inc., |
(3) | Registration Statement (Form S-8 No. 333-202677) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan, |
(4) | Registration Statement (Form S-8 No. 333-195170) pertaining to the Eleven Biotherapeutics, Inc. Amended and Restated 2009 Stock Incentive Plan, 2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan, and |
(5) | Registration Statement (Form S-8 No. 333-210523) pertaining to the Eleven Biotherapeutics, Inc. 2014 Stock Incentive Plan; |
of our report dated March 24, 2017, with respect to the financial statements of Eleven Biotherapeutics, Inc. included in this Annual Report (Form 10-K) of Eleven Biotherapeutics, Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 24, 2017